Welcome to our dedicated page for Century Therapeutics news (Ticker: IPSC), a resource for investors and traders seeking the latest updates and insights on Century Therapeutics stock.
Century Therapeutics, Inc. (NASDAQ: IPSC) is a biotechnology company at the forefront of advancing cell therapies for cancer and autoimmune diseases. Utilizing adult stem cells, specifically induced pluripotent stem cells (iPSCs), Century Therapeutics leverages its proprietary Allo-Evasion™ technology to develop curative therapies that overcome the limitations of first-generation cell therapies.
The company's innovative platform integrates several advanced technologies including CRISPR-mediated gene editing, proprietary chimeric antigen receptors (CARs), and cutting-edge manufacturing capabilities. These combined elements enhance cell product performance, prevent host immune system rejection, and minimize development risks, positioning Century Therapeutics as a leader in the biotech sector.
Key Candidates and Achievements
- CNTY-101: An investigational CD19-targeting iPSC-derived natural killer (NK) cell therapy, CNTY-101 is designed for treating relapsed or refractory non-Hodgkin lymphoma (NHL). This product incorporates six precision gene edits and has shown promising early response signals, including complete and partial responses in clinical trials.
- Allo-Evasion™ Technology: Core to Century's strategy, this technology enables repeat dosing without the need for continual lymphodepletion, significantly improving patient outcomes. The company presented comprehensive data demonstrating the protective capabilities of its Allo-Evasion™ edits at major scientific conferences.
- Dual-Targeting CARs: Century has developed a novel CD19xCD22 bispecific CAR, demonstrating effective cytotoxicity against tumors in preclinical models, further expanding the potential applications of its therapies.
Recent News and Developments
- Clinical Trial Success: The ELiPSE-1 Phase 1 trial showcased encouraging initial data for CNTY-101, revealing its potential in treating aggressive B-cell lymphomas.
- New Partnerships and Acquisitions: The acquisition of Clade Therapeutics, a leader in iPSC-derived αβ T cells, enhances Century's pipeline, technology, and expertise in the cell therapy space.
- Financial Growth: Century recently secured $60 million in private placement funding, underscoring investor confidence in its strategic direction and potential market impact.
- Research Expansion: The company is expanding its clinical development into autoimmune disease indications, with a focus on leveraging its iPSC platform to address significant unmet medical needs.
For more detailed information about Century Therapeutics and its groundbreaking work in cell therapy, visit www.centurytx.com.
Rhea-AI Summary
Century Therapeutics (NASDAQ: IPSC) will participate in Chardan’s 8th Annual Genetic Medicines and Cell Therapy Manufacturing Summit with a fireside chat and panel discussion. The events will focus on iPSC-derived cell therapies in immuno-oncology and autoimmune and inflammatory diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.62%
Tags
-
Rhea-AI Summary
Century Therapeutics (NASDAQ: IPSC) expands its iPSC-derived iNK cell therapy, CNTY-101, into additional autoimmune disease indications. A $60 million private placement supports this expansion, extending the cash runway into 2026. The acquisition of Clade Therapeutics enhances Century's position in allogeneic, iPSC-derived cell therapy with new pipeline programs in cancer and autoimmune diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.14%
Tags
-
Rhea-AI Summary
Century Therapeutics (NASDAQ: IPSC) presents promising preclinical data at AACR Annual Meeting 2024, showcasing advancements in iPSC-derived cell therapies for immuno-oncology and autoimmune diseases. The data highlights innovative gene editing, protein engineering, and manufacturing capabilities, including a dual-targeting CAR for B cell malignancies and enhanced protection against rejection through Allo-Evasion™ technology.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.08%
Tags
News
Rhea-AI Summary
Century Therapeutics (NASDAQ: IPSC) will participate in a fireside chat at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference. The event will focus on the development of iPSC-derived cell therapies in immuno-oncology and autoimmune and inflammatory disease.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.05%
Tags
-
Rhea-AI Summary
Century Therapeutics, Inc. (NASDAQ: IPSC) reported financial results and key developments for the year 2023. The company presented positive data from the Phase 1 ELiPSE-1 Trial of CNTY-101 in B-cell lymphomas, received IND clearance for CNTY-101 in SLE, and plans to initiate the CALiPSO-1 trial in 2024. Century ended 2023 with $261.8 million in cash and a cash runway into 2026.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.2%
Tags
-
Rhea-AI Summary
Century Therapeutics (NASDAQ: IPSC) announces preclinical data presentation at the 2024 AACR Annual Meeting showcasing iPSC-derived cell therapy capabilities in immuno-oncology and autoimmune diseases. The data includes advancements in iPSC reprogramming, gene editing, protein engineering, and computational biology.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
17.65%
Tags
Rhea-AI Summary
Century Therapeutics (NASDAQ: IPSC) will participate in a fireside chat at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference on February 8th, 2024. The event will be available for replay on the company's website for 90 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.17%
Tags
-
Rhea-AI Summary
Century Therapeutics (NASDAQ: IPSC) presents initial clinical data at 65th ASH Annual Meeting, demonstrating encouraging results for CNTY-101 in R/R B-cell lymphoma patient. The data indicates potential for a multi-dosing strategy without the need for lymphodepletion, positioning CNTY-101 to fill an unmet need among heavily pretreated non-Hodgkin lymphoma patients. The company plans to advance the study at higher doses and present additional clinical data in mid-2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Century Therapeutics (NASDAQ: IPSC) will discuss initial clinical data supporting a multi-dosing strategy from its ongoing first-in-human Phase 1 ELiPSE-1 trial of CNTY-101, the Company’s lead allogeneic, iPSC-derived CAR-iNK cell therapy, in relapsed/refractory CD19 positive B-cell lymphomas. The Company will also present additional results from patients treated at Dose Level 1 (100 million cell dose), as well as preliminary data from patients treated at Dose Level 2 (300 million cell dose). Additionally, Century Therapeutics will discuss its planned Phase 1 trial, including supporting preclinical data, for CNTY-101 in systemic lupus erythematosus, the first autoimmune and inflammatory disease indication for CNTY-101.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
36.08%
Tags
Rhea-AI Summary
Century Therapeutics (NASDAQ: IPSC) has received clearance from the U.S. FDA for its Phase 1 clinical trial to assess CNTY-101, an iPSC-derived cell therapy, in patients with systemic lupus erythematosus (SLE). This marks the second IND clearance for CNTY-101 and the first for an autoimmune and inflammatory disease indication. CNTY-101 is engineered with six precision gene edits and is designed to address the unmet medical needs of SLE patients. The Phase 1 clinical trial is set to begin in the first half of 2024, with initial data expected by the end of 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
36.08%
Tags
FAQ
What is the current stock price of Century Therapeutics (IPSC)?
The current stock price of Century Therapeutics (IPSC) is $0.8972 as of January 21, 2025.
What is the market cap of Century Therapeutics (IPSC)?
The market cap of Century Therapeutics (IPSC) is approximately 78.1M.
What is Century Therapeutics' primary focus?
Century Therapeutics specializes in developing iPSC-derived cell therapies to treat cancer and autoimmune diseases, leveraging its Allo-Evasion™ technology.
What is CNTY-101?
CNTY-101 is an investigational CD19-targeting iPSC-derived NK cell therapy designed to treat relapsed or refractory non-Hodgkin lymphoma, incorporating six precision gene edits.
How does Century Therapeutics' Allo-Evasion™ technology work?
Allo-Evasion™ technology enables cell therapies to evade the host immune system, allowing for repeat dosing without continual lymphodepletion, improving treatment efficacy and patient outcomes.
What recent achievements has Century Therapeutics made?
Century has demonstrated promising clinical data for CNTY-101, expanded its pipeline through the acquisition of Clade Therapeutics, and secured $60 million in private placement funding.
What are the potential applications of Century's dual-targeting CARs?
Century's dual-targeting CARs, such as the CD19xCD22 bispecific CAR, have shown effectiveness against tumors in preclinical models and expand the therapeutic potential beyond current CAR-T therapies.
What are Century Therapeutics' plans for autoimmune diseases?
Century plans to expand CNTY-101's clinical development into autoimmune disease indications, leveraging its iPSC technology to address significant unmet needs in these areas.
How does Century Therapeutics ensure the safety of its cell therapies?
Century engineers its iPSC-derived cell therapies with safety switches and advanced genetic edits to enhance safety, reduce adverse effects, and improve efficacy.
What financial milestones has Century Therapeutics recently achieved?
Century recently completed a $60 million private placement and acquired Clade Therapeutics, strengthening its financial position and expanding its pipeline.
Where can I find more information about Century Therapeutics?
For more detailed information, visit Century Therapeutics' official website at www.centurytx.com.
What partnerships does Century Therapeutics have?
Century leverages key collaborative relationships for developing and manufacturing its product candidates, further supported by recent strategic acquisitions and partnerships.
Century Therapeutics, Inc.
Nasdaq:IPSC
IPSC Rankings
IPSC Stock Data
78.06M
60.23M
28.07%
61.11%
3.18%
Biotechnology
Biological Products, (no Disgnostic Substances)
United States of America
PHILADELPHIA